RBZ.V · 2020-01-03 12:00:00

Enters into Amending Agreement with Alzex Biomedical Group Inc.

Mergers & Acquisitions

REBEL CAPITAL 2.0 CORP.

ENTERS INTO AMENDING AGREEMENT WITH

ALZEX BIOMEDICAL GROUP INC.

TSX Venture: RBZ.P FOR IMMEDIATE RELEASE

CALGARY, ALBERTA – May 8, 20 20 – Rebel Capital 2.0 Corp. (" Rebel" or the

"Corporation") provides an update on the previously announced transaction whereby Rebel

expects to complete a business combination with Alzex Biomedical Group Inc. ( “Alzex”)

pursuant to a definitive agreement dated January 3 , 2020 between Rebel and Alzex (the

“Definitive Agreement ”) that, if completed, would constitute Rebel's "Qualifying

Transaction" (as such term is defined in TSX Venture Exchange ("TSXV") Policy 2.4 – Capital

Pool Companies) (the "Transaction").

Pursuant to an amending agreement dated May 7, 2020 (with effect as and from March 31,

2020) to the Definitive Agreement, the parties to the Definitive Agreement have agreed to

extend the outside date for the closing date of the Transaction to September 15, 2020. This

amendment allows additional time for Rebel and Alzex to comple te material elements of the

Definite Agreement required in order to complete the proposed Qualifying Transaction.

Further information regarding the Transaction is provided in Rebel’s press releases dated

September 30, 2019 and January 7, 2020 available under Rebel’s profile on www.sedar.com.

About Rebel Capital 2.0 Corp

Rebel Capital is a capital pool company ("CPC") within the meaning of the policies of the TSXV

that has not commenced commercial operations and has no assets other than cash. The board

of directors of the Corporation consist of Charles MaLette, Doug Bachman and Lance Morginn.

The officers of the Corporation are Charles MaLette (CEO), and Lance Morginn (CFO).

Completion of the Transaction is subject to a number of conditions inc luding, but not limited to, TSXV

acceptance. Where applicable, the Transaction cannot close until the required shareholder approval is

obtained. There can be no assurance that the Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the Filing Statement to be prepared in connection

with the Transaction, any information released or received with respect to the Transaction may not be

accurate or complete and should not be relied upon. Trading in the securities of a capital pool company

should be considered highly speculative.

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed Transaction and

has neither approved nor disapproved the contents of this Press Release.

For further information please contact:

Rebel Capital 2.0 Corp.: Alzex Bio Medical Inc.:

Charles MaLette Fern Turner – Director

Telephone: (604) 428-5171